

# Corporate Risk Management



**NHS Lanarkshire Board**  
**25<sup>th</sup> October 2023**

**Subject: Corporate Risk Register Overview**

## 1. Purpose

---

This paper is coming to the Board for:

|               |  |                 |  |         |   |
|---------------|--|-----------------|--|---------|---|
| For assurance |  | For endorsement |  | To note | X |
|---------------|--|-----------------|--|---------|---|

## 2. Route to Board

This paper has been:

|          |   |          |  |          |  |
|----------|---|----------|--|----------|--|
| Prepared | X | Reviewed |  | Endorsed |  |
|----------|---|----------|--|----------|--|

By the Board Secretary, Corporate Business Manager and Corporate Management Team at its meeting held on 2<sup>nd</sup> October 2023.

## 3. Background and Summary of Key Issues

Effective Risk Management is a fundamental cornerstone of good Corporate Governance and Internal Control and is an essential component in the delivery of the NHS Board's corporate objectives.

The NHS Lanarkshire corporate risk register is considered frequently by the corporate management team, who discuss new and emerging risks; very high graded risks across NHS Lanarkshire, mitigating controls and risks that exceed the corporate risk appetite.

The enclosed report (appendix 1) and the subsequent Corporate Risk Register in full (appendix 2) presents an update to the Corporate Risk Register for the reporting period August 2023/24 – October 2023/24.

Summary of material changes to the risks within the Corporate Risk Register. **For note** all details that follow were previously reported to the Board in August 2023. Due to the overlap in reporting periods, all of the following changes remain current within the period being reported in this report:

- One new risk **2234** – Nursing Home Beds which was subsequently reviewed by CMT with score decreased.
- One risk was escalated: **2230** – UHM Fire Safety Waste Receptacles
- One risk was de-escalated: **2205** – Fire Safety Within NHSL
- One risk was closed: **2220** – Junior Doctor Industrial Action

- Two risks have been closed and removed from the Corporate Risk Register: **2125** – Optimal Clinical Outcomes & **2220** – Junior Doctors Industrial Action

The risk around demographic changes raised at a previous Board meeting has been discussed by the Corporate Management Team and further refinement is required to better define the risk, and scope out the mitigation and controls. It is hoped to have completed this in time for consideration in the next Board report.

The potential risk raised at the last PPRC meeting around the Equalities etc legislation is being taken forward with Mr Lee separately.

#### 4. Strategic Context

This paper links to the following:

|                          |   |                       |  |                      |   |
|--------------------------|---|-----------------------|--|----------------------|---|
| Corporate objectives     | X | AOP                   |  | Government policy    |   |
| Government directive     |   | Statutory requirement |  | AHF / local policy   |   |
| Urgent operational issue |   | Other                 |  | Corporate Governance | X |

#### 5. Contribution to Quality

This paper aligns to the following elements of safety and quality improvement:

**Three Quality Ambitions:**

|      |   |           |   |                |   |
|------|---|-----------|---|----------------|---|
| Safe | X | Effective | X | Person Centred | X |
|------|---|-----------|---|----------------|---|

#### 6. Measures for Improvement

The presentation of these reports has been revised in line with the expectations of Non-Executives to use more infographics, and the reports will continue to evolve. Measures for improvement for each risk are captured in the controls and mitigation sections to reduce the impact and likelihood of each risk.

#### 7. Financial Implications

All very high and high graded risks will be considered in terms of exceeding the corporate risk appetite against the adequacy of mitigating controls and action planning that might require a more intensive supported financial approach to mitigation.

#### 8. Risk Assessment/Management Implications

No further risk analysis is required.

#### 9. Fit with Best Value Criteria

This paper aligns to the following best value criteria:

|                       |   |                        |   |                               |   |
|-----------------------|---|------------------------|---|-------------------------------|---|
| Vision and leadership | X | Effective partnerships |   | Governance and accountability | X |
| Use of resources      | X | Performance management | X | Equality                      |   |
| Sustainability        |   |                        |   |                               |   |

## 10. Equality and Diversity Impact Assessment

An E&D Impact Assessment has been completed

Yes   
 No

An equality and diversity impact assessment is not required for this report, as the approach applies equally.

## 11. Consultation and Engagement

This paper has been discussed and endorsed by CMT and prepared for onwards assurance to the Board.

## 12. Actions for the Board

The Board are asked to:

|         |   |                            |  |                          |  |
|---------|---|----------------------------|--|--------------------------|--|
| Approve |   | Endorse                    |  | Identify further actions |  |
| Note    | X | Accept the risk identified |  | Ask for a further report |  |

Board members are asked to:

- Consider the content of the attached report in Appendix 1 for approval.

## 13. Further Information

For further information about any aspect of this paper, please contact:

|                 |                            |                     |
|-----------------|----------------------------|---------------------|
| Mr P Cannon     | Ms Allison Mclean          | Professor J Gardner |
| Board Secretary | Corporate Business Manager | Chief Executive     |